Abstract
The antiplatelet therapy is the maint therapeutic strategy in patients in high cardiovascular risk - in acute coronary syndromes, post MI or in coronary interventions. n patients with a higher risk of complications, as is the case in patients with acute coronary events after coronary intervention, especially if the implanted stent is indicated by a combination of dual antiplatelet therapy of aspirin and clopidogrel. Cheaper alternative for acute coronary events is a combination of aspirin with prasugrel.
Patients after stroke is a treatment option dual antiplatelet therapy with acetylsalicylic acid, dipyridamole, however, is as effective monotherapy with clopidogrel. Whether this treatment is better than the optimal dose of aspirin is not supported.
Direct comparison indicates equivalence with clopidogrel treatment. In patients with atrial fibrillation is still true that the optimal approach is to anticoagulant therapy in case of impossibility to use anticoagulant therapy, antiplatelet therapy can be accepted - however, the optimal monotherapy